---
title: "Phio Pharmaceuticals Corp. (PHIO.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PHIO.US/overview.md"
symbol: "PHIO.US"
name: "Phio Pharmaceuticals Corp."
parent: "https://longbridge.com/en/quote/PHIO.US.md"
datetime: "2026-04-17T00:47:41.767Z"
locales:
  - [en](https://longbridge.com/en/quote/PHIO.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PHIO.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PHIO.US/overview.md)
---

# Phio Pharmaceuticals Corp. (PHIO.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 411 Swedeland Road, Suite 23-1080, King Of Prussia, Pennsylvania, United States |
| Website | [iopharma.com](https://iopharma.com) |

## Company Profile

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.

## Key Executives

| Name | Title |
|------|-------|
| Robert J. Bitterman | President, CEO & Chairman |
| Lisa C. Carson | CFO, Principal Accounting Officer and VP of Finance & Administration |
| Linda M. Mahoney | Senior Vice President of Development |
| Jennifer Phillips | Senior Vice President of Regulatory & Corporate Affairs |
| Curtis A. Lockshin | Independent Director |
| Jonathan E. Freeman | Independent Director |
| Patricia A. Bradford | Independent Director |
| David H. Deming | Lead Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Orca Capital GmbH | 4.64% | 2025-12-08 |
| Geode Capital Management, LLC | 0.80% | 2025-12-31 |
| The Vanguard Group, Inc. | 0.75% | 2025-12-31 |
| Macquarie Investment Management Business Trust | 0.43% | 2025-12-31 |
| Cetera Investment Advisers LLC | 0.37% | 2025-12-31 |
| Robert J. Bitterman | 0.36% | 2026-02-05 |
| Northern Trust Global Investments | 0.20% | 2025-12-31 |
| DRW Holdings, LLC | 0.19% | 2025-12-31 |
| Susquehanna International Group, LLP | 0.17% | 2025-12-31 |
| Robert L. Ferrara | 0.13% | 2025-09-11 |

## Business Breakdown

| Segment | Revenue | Ratio |
|---------|---------|-------|
| Biotechnology (Startups) | 21000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Phio Pharmaceuticals Corp. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Biotechnology (Startups)",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## Geographic Segments

| Region | Revenue | Ratio |
|--------|---------|-------|
| United States | 21000 | 100% |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**